What Is The History Of Meth

The Actual History Of Methamphetamine

Methamphetamine first appeared in laboratory records in 1893, when a chemist named Nagayoshi Nagai isolated it from ephedrine, a compound found in the plant Ephedra sinica. The Japanese pharmacological community took note, but it wasn't until 1919 that Akira Ogata developed a method to produce it in pure crystalline form using red phosphorus and iodine. That process is still the foundational chemistry behind most illicit meth production today, nearly a century later. During World War II, the Japanese military distributed meth to pilots and soldiers to stave off fatigue. It was called Pice amphetamine at the time. American forces had their own version — Benzedrine — a prescription inhaler and tablet that contained amphetamine and was widely distributed to troops. After the war, surplus pharmaceutical meth ended up in civilian hands, and the first wave of recreational use hit American bases in the 1940s and 50s. Veterans came home with prescriptions, and the habit followed them.

What Is The History Of Meth In America?

In the United States, methamphetamine was classified as a Schedule II controlled substance under the Controlled Substances Act of 1970, meaning it was recognized as having a medical use but also a high potential for abuse. The prescription brand Desoxyn, which is still FDA-approved today for ADHD and obesity, contains methamphetamine hydrochloride at doses far below what a recreational user would encounter. The 1960s and 70s saw meth culture take root in specific regions — the Sun Belt, motorcycle clubs, long-haul truckers, and rural communities where the drug was cheap and readily available. Unlike cocaine, which required importation through coastal cities, meth could be manufactured anywhere with the right precursors. That decentralization made it impossible to control through border enforcement alone. The 1980s brought the Combat Intelligence Sharing Act and increased DEA focus on meth, but the real turning point was the mid-1990s when the Methamphetamine Anti-Proliferation Act restricted sales of pseudoephedrine, a key precursor. This pushed production underground. Laboratory-style meth gave way to the "shake and pour" method, which required less equipment and could be set up in motel rooms, trailers, and borrowed garages. The quality dropped, but the availability skyrocketed.

By the early 2000s, Mexican cartons had taken over large-scale production, shifting from pseudoephedrine-based methods to the much more efficient phenyl-2-propanone (P2P) route. This produced meth with higher purity and at scales that domestic shake-and-pour operations simply couldn't match. The result was a flood of cheap, high-purity meth into American markets and a dramatic spike in overdose deaths and addiction rates, particularly in the Midwest and Southwest. I worked in a public health lab in the Pacific Northwest during the late 2000s, and one thing that stood out was how quickly the chemistry of the street supply shifted. We'd be analyzing seized samples for months and then suddenly the impurity profiles changed overnight — new cutting agents, different byproducts, completely different regional sources. The supply chain moved faster than any enforcement strategy could track. There's no real workaround for that kind of volatility. You adapt your testing protocols and hope you're not behind the curve by too much. The 2010s and 2020s have seen meth deaths climb steadily. The CDC reported over 50,000 meth-related overdose deaths in a single year recently, a number that surprised many public health officials who had been tracking fentanyl as the primary overdose driver. Meth and fentanyl now frequently appear together in the supply, which complicates treatment and harm reduction efforts significantly.

Pharmaceutical meth remains available by prescription, though it's rarely prescribed due to stigma and the availability of non-stimulant alternatives for ADHD. The industrial precursors are heavily monitored in the US, but international diversion of chemicals from countries with looser regulations remains a persistent bottleneck for enforcement.